Economic and Organizational Advantages of Bictegravir/Alafenamide Tenofovir/Emtricitabine for HIV Treatment

Author(s)

Ferrario LB1, Menzaghi B2, Rizzardini G3, Bellavia D4, Schettini F1, Garagiola E1, Foglia E1
1LIUC University, Castellanza, Italy, 2ASST Valle Olona, Busto Arsizio, Italy, 3ASST Fatebenefratelli Sacco, Milan, Italy, 4LIUC University, Castellanza, VA, Italy

OBJECTIVES: Given the availability of a growing number of HIV treatment options, this study aims to generate economic and organizational evidence that may support a rational use of resources for the treatment of both naïve and experienced HIV individuals, within the Italian National Healthcare Service (NHS), operating informed and conscious choices.

METHODS: A budget impact analysis, representing the Italian NHS healthcare expenditure evolution over three years, was developed, considering the overall Italian HIV treated population (N=101,819: 24,916 treatment-naïve and 76,903 treatment-experienced individuals). Patient’s treatment history, treatment regimen, development of adverse events, achievement of an undetectable viral load and direct healthcare total costs were the model input variables. Scenario A, representative of the current situation of consumption and penetration rate of the different therapeutic alternatives (derived from the most update guidelines), was compared with a Scenario B, assuming a greater adoption of BIC/FTC/TAF.

Data were collected from scientific evidence, Italian national and regional legislations, and healthcare professionals’ reports. Results are expressed both in economic and organizational terms.

RESULTS: From an economic perspective, any modification in the current case-mix of HIV therapy (thus hypothesizing a greater use of BIC/FTC/TAF) is related to an economic saving equal to -€26.040.271, in total health spending, for the Italian NHS. From an organizational perspective, this modification would reduce the overall hospital accesses devoted to the management of adverse events and/or complications, generating an overall saving of 245,938 hours, considering the time spent by the healthcare professionals involved in the care and treatment of individuals with HIV.

CONCLUSIONS: BIC/FTC/TAF represents an interesting possibility for the rapid initiation of ART, as well as for switches, being able to optimize the clinical pathway of a patient with HIV, from an economic and organizational perspective.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

EE214

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×